



Environment and Radiation Section: research interests & competencies

International Agency for Research on Cancer
Lyon, France

Partnering event,
Information Day on the 1st Open RTD Call of the CONCERT-European Joint Program for
the Intergration of Radiation protection Research under Horizon 2020
January 27, 2016

The International Nuclear Workers Study (INWORKS)

- >300,000 nuclear workers from France, UK and USA
- Continuous mortality follow-up
- Important findings on solid cancer & leukemia risks following low-dose rate occupational exposure (Richardson D *et al*, BMJ, 2015; Leuraud K *et al*, Lancet Haematol, 2015)

EPI-CT Project

Grant agreement no.: **269912** with the EU
under the EURATOM FP7 Programme

- Epidemiological study to quantify risks for paediatric computerised tomography (CT) and to optimise doses
- >1,000,000 children patients
- Data on CT procedures from 9 European countries
- Sophisticated dosimetry
- Assessment of leukemia & solid cancer risks following CT procedures

International Agency for Research on Cancer



Cooperation on Chernobyl Health Research (CO-CHER)

Grant agreement no 605302 (CO-CHER) with the EU
under the EURATOM FP7 Programme

- A collaboration effort bringing together key research institutions involved in Chernobyl health effect studies worldwide
- Setting up a Lifespan Cohorts of liquidators and exposed children with direct thyroid measurements and *in utero* exposed
- Defining future research priorities and sustaining Chernobyl research

International Agency for Research on Cancer



SEMI-NUC

Grant agreement no 323310 (SEMI-NUC) with the EU
under the EURATOM FP7 Programme

- A roster of about 300,000 people exposed to wide range of doses due to nuclear tests in 1949-89 in Semipalatinsk, Kazakhstan
- To assess feasibility of
 - setting up a cohort(s) of exposed population for a long-term full-scale prospective research
 - Individual dose reconstruction from external and internal exposures




DE LA RECHERCHE À L'INDUSTRIE



FRENCH HAEMANGIOMA COHORT

LAURE PIQUERET-STEPHAN, DR. MONIKA FRENZEL, MICHELLE RICOUL,
DR. FLORENT DE VATHAIRE AND DR. LAURE SABATIER



- **Effect of low dose irradiation?**
- High interest in analyzing data of *in vivo* studies
- Searching for **biomarkers**
- **Risk assessment**


PROCyTOX – CEA Fontenay aux Roses

MÜNCHEN 2016

French haemangioma cohort

Haemangioma:

- benign, and usually self-involuting mass of endothelial cells that line blood vessels (estrogen induced?!)
- 3–5% of new born are having a haemangioma
- 2-3x more often for girls than for boys
- usually appears the first weeks of life and generally resolves by age 10
- approximately 80% are located on the face and neck (organ: liver)



- Treatment between **1940-1973** → (age in 2014: **40-73 years old**)
- 8335 patients in total (**4767 patients chosen for EpiRadBio**)
- Treatment for EpiRadBio-candidates before the **age of 3**
- In the cases of radiation therapy: **²²⁶Ra, X-rays, ³²P, ⁹⁰Y or ⁹⁰Sr**
- Thereby, only **low doses in regions developing tumors** (i.e. breast, skin and thyroid)
- Some without treatment or cryotherapy

Site	IGR study Dose (mGy)
Active marrow	53
Brain	89
Breast	110
Colon	15
Lung	6
Thyroid	39

French haemangioma cohort



PRO:


- 1. Homogeneous cohort:**
in fact normal population, just characterized by having a haemangioma
- 2. Medical documents** of haemangioma radiotherapy available
- 3. Long follow-up**
- 4. Volunteers** that filled already a **questionnaire for epidemiological studies**
- 5. Dose estimation for every major organ** was performed

CONTRA:

- 1. Healthy donors:** no regular visits to hospitals
- 2. Irradiated as babies => treatment unknown**
- 3. Questionnaire (10 years ago)**


Dosimetry:

- Mathematical computer models are used to simulate a person of any age, based on body-size measurements
- Taking into account the surface of the applicators (cm²)



ITCA software for brachytherapy


Category	Dose at bone marrow (Gy)
0	0
1	Treated/no dose at BM
2	$> 0 < 0.001$
3	$> 0.001 < 0.01$
4	$> 0.01 < 0.05$
5	$> 0.05 < 0.1$
6	> 0.1



Dos_EG software for EBRT

FHC-BIOBANK – BLOOD LYMPHOCYTES

11 380 samples
from 369 donors



FUTURE PLANS CONCERT CALL TOPIC 1 – **CANCER EFFECTS**

1. Focus on polymorphism of individual telomere length
 - a) as driving force to unmask recessive radiation induced mutations
 - b) Contribution in tumoral initiation and progression

FUTURE PLANS CONCERT CALL TOPIC 1 – **NON CANCER EFFECTS**

1. Study telomere length as biomarker and prognostic factor for cardiovascular diseases
2. Categorization of FHC donors according to DNA repair capacities
 - a) Kinetic experiments using γ H2AX and/or 53BP1
 - b) Chromosomal aberrations/fragmentation with PCC
 - c) and further correlation with appearance of cerebral/vascular diseases and telomeric pair mutations (CEREBRAD)


Thank you



Laure Sabatier
Monika Frenzel
Aude Lenain
Michelle Ricoul
Sophie Bénard
Annie Vernique
Laure Piqueret-Stephan



Dr. Florent de Vathaire
Marion Bellamy-Agbe
Mohamed Amine Benadjaoud



Funding:

